These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1387 related items for PubMed ID: 28646772

  • 1. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.
    Le Burel S, Champiat S, Mateus C, Marabelle A, Michot JM, Robert C, Belkhir R, Soria JC, Laghouati S, Voisin AL, Fain O, Mékinian A, Coutte L, Szwebel TA, Dunogeant L, Lioger B, Luxembourger C, Mariette X, Lambotte O.
    Eur J Cancer; 2017 Sep; 82():34-44. PubMed ID: 28646772
    [Abstract] [Full Text] [Related]

  • 2. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    Ruste V, Goldschmidt V, Laparra A, Messayke S, Danlos FX, Romano-Martin P, Champiat S, Voisin AL, Baldini C, Massard C, Laghouati S, Marabelle A, Lambotte O, Michot JM.
    Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
    [Abstract] [Full Text] [Related]

  • 3. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
    Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, Champiat S, Chahine C, Robert C, Herbaux C, Besse B, Guillemin A, Mateus C, Pautier P, Saïag P, Madonna E, Maerevoet M, Bout JC, Leduc C, Biscay P, Quere G, Nardin C, Ebbo M, Albigès L, Marret G, Levrat V, Dujon C, Vargaftig J, Laghouati S, Croisille L, Voisin AL, Godeau B, Massard C, Ribrag V, Marabelle A, Michel M, Lambotte O.
    Lancet Haematol; 2019 Jan; 6(1):e48-e57. PubMed ID: 30528137
    [Abstract] [Full Text] [Related]

  • 4. Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies.
    Baldini C, Martin Romano P, Voisin AL, Danlos FX, Champiat S, Laghouati S, Kfoury M, Vincent H, Postel-Vinay S, Varga A, Vuagnat P, Ribrag V, Mezquita L, Besse B, Hollebecque A, Lambotte O, Michot JM, Soria JC, Massard C, Marabelle A.
    Eur J Cancer; 2020 Apr; 129():71-79. PubMed ID: 32143106
    [Abstract] [Full Text] [Related]

  • 5. Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy.
    Bitton K, Michot JM, Barreau E, Lambotte O, Haigh O, Marabelle A, Voisin AL, Mateus C, Rémond AL, Couret C, Champiat S, Labetoulle M, Rousseau A.
    Am J Ophthalmol; 2019 Jun; 202():109-117. PubMed ID: 30772350
    [Abstract] [Full Text] [Related]

  • 6. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.
    Belkhir R, Burel SL, Dunogeant L, Marabelle A, Hollebecque A, Besse B, Leary A, Voisin AL, Pontoizeau C, Coutte L, Pertuiset E, Mouterde G, Fain O, Lambotte O, Mariette X.
    Ann Rheum Dis; 2017 Oct; 76(10):1747-1750. PubMed ID: 28600350
    [Abstract] [Full Text] [Related]

  • 7. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
    Michot JM, Lazarovici J, Tieu A, Champiat S, Voisin AL, Ebbo M, Godeau B, Michel M, Ribrag V, Lambotte O.
    Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
    [Abstract] [Full Text] [Related]

  • 8. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X, Roudi R, Dai T, Chen S, Fan B, Li H, Zhou Y, Zhou M, Zhu B, Yin C, Li B, Li X.
    BMC Cancer; 2019 Jun 10; 19(1):558. PubMed ID: 31182061
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy.
    Narváez J, Juarez-López P, LLuch J, Narváez JA, Palmero R, García Del Muro X, Nolla JM, Domingo-Domenech E.
    Autoimmun Rev; 2018 Oct 10; 17(10):1040-1045. PubMed ID: 30103042
    [Abstract] [Full Text] [Related]

  • 11. Autoimmune complications of immunotherapy: pathophysiology and management.
    Chan KK, Bass AR.
    BMJ; 2020 Apr 06; 369():m736. PubMed ID: 32253223
    [Abstract] [Full Text] [Related]

  • 12. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study.
    Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C, Dousset L, Pham-Ledard A, Prey S, Beylot-Barry M, Daste A, Gross-Goupil M, Lallier J, Ravaud A, Forcade E, Bannwarth B, Truchetet ME, Richez C, Mehsen N, Schaeverbeke T, FHU ACRONIM.
    Ann Rheum Dis; 2018 Mar 06; 77(3):393-398. PubMed ID: 29146737
    [Abstract] [Full Text] [Related]

  • 13. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
    De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, Roche B, Antonini TM, Coilly A, Laghouati S, Robert C, Marabelle A, Guettier C, Samuel D.
    J Hepatol; 2018 Jun 06; 68(6):1181-1190. PubMed ID: 29427729
    [Abstract] [Full Text] [Related]

  • 14. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V.
    Am J Clin Dermatol; 2018 Jun 06; 19(3):345-361. PubMed ID: 29256113
    [Abstract] [Full Text] [Related]

  • 15. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
    Cortellini A, Bersanelli M, Santini D, Buti S, Tiseo M, Cannita K, Perrone F, Giusti R, De Tursi M, Zoratto F, Marconcini R, Russano M, Zeppola T, Anesi C, Filetti M, Marchetti P, Botticelli A, Gelibter A, De Galitiis F, Vitale MG, Rastelli F, Tudini M, Silva RR, Atzori F, Chiari R, Ricciuti B, De Giglio A, Migliorino MR, Mallardo D, Vanella V, Mosillo C, Bracarda S, Rinaldi S, Berardi R, Natoli C, Ficorella C, Porzio G, Ascierto PA.
    Eur J Cancer; 2020 Mar 06; 128():17-26. PubMed ID: 32109847
    [Abstract] [Full Text] [Related]

  • 16. Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey.
    Ghosh N, Tirpack A, Chan KK, Bass AR.
    J Immunother Cancer; 2020 Oct 06; 8(2):. PubMed ID: 33067320
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab.
    Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U, Lipson EJ, Bleich KB, Shah AA, Naidoo J, Brahmer JR, Le D, Bingham CO.
    Ann Rheum Dis; 2017 Jan 06; 76(1):43-50. PubMed ID: 27307501
    [Abstract] [Full Text] [Related]

  • 19. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.
    Anderson R, Theron AJ, Rapoport BL.
    Front Immunol; 2019 Jan 06; 10():2254. PubMed ID: 31616428
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.
    Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L, Champiat S, Aspeslagh S, Haroche J, Albiges L, Massard C, Girard N, Dalle S, Besse B, Laghouati S, Soria JC, Mateus C, Robert C, Lanoy E, Marabelle A, Lambotte O.
    Eur J Cancer; 2018 Mar 06; 91():21-29. PubMed ID: 29331748
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 70.